11.06.2024 - Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, .
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership.
REYKJAVIK, Iceland, Jan. 19, 2024 Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the.
Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement Relates to the submission of a marketing approval application in JapanMarks strong progress in 2016 agreement and further boosts Mithra’s cash positionAdditional EUR 10 million in milestone payments expected at approval of marketing authorizationMithra eligible for revenue from supply of the manufactured product post-commercialization Liege, Belgium, 23 October 2023 – 07:00 CEST – Mithra (Euro
25.09.2023 - REYKJAVIK, Iceland, Sept. 25, 2023 (GLOBE NEWSWIRE) - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization . Seite 1